Bristol-Myers Squibb Says MS Drug Launch Delayed due to COVID-19

Bristol-Myers Squibb is delaying the launch of its multiple-sclerosis drug Zeposia (ozanimod) due to the COVID-19 pandemic.

The company originally planned to launch the product as soon as it was approved, which the FDA did yesterday.

Zeposia was approved for treating adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.